Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 9:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 605 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Epileptic Seizures Clear all
Completed Phase 3 Interventional

Depression and Health Outcomes in Refractory Epilepsy

NCT00026637
View directory record Official record
Conditions
Depression, Epilepsy
Interventions
sertraline, cognitive behavior therapy
Drug · Behavioral
Lead sponsor
Columbia University
Other
Eligibility
21 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
2
States / cities
St Louis, Missouri • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Sep 30, 2026, 9:08 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)

NCT04873869
View directory record Official record
Conditions
SCN8A Developmental and Epileptic Encephalopathy Syndrome
Interventions
NBI-921352, Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
2 Years to 21 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
San Francisco, California • Washington D.C., District of Columbia • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Sep 30, 2026, 9:08 AM EDT
Completed No phase listed Observational

Phenotype and Etiology of Pallister-Hall Syndrome

NCT00001404
View directory record Official record
Conditions
Malformations, Multiple Abnormalies, Polydactyly
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
Not listed
Enrollment
1,170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2016
U.S. locations
3
States / cities
Los Angeles, California • Bethesda, Maryland • Greenwood, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Sep 30, 2026, 9:08 AM EDT
Recruiting No phase listed Observational

Biology of Juvenile Myoclonic Epilepsy

NCT03400371
View directory record Official record
Conditions
Juvenile Myoclonic Epilepsy
Interventions
Blood draw, Existing samples
Other
Lead sponsor
King's College London
Other
Eligibility
10 Years to 40 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
3
States / cities
New York, New York • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 5, 2025 · Synced Sep 30, 2026, 9:08 AM EDT
Completed Phase 3 Interventional Results available

A 2-Part Study to Investigate the Dose-Ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children ≥ 2 Years Old and Young Adults With Dravet Syndrome

NCT02926898
View directory record Official record
Conditions
Dravet Syndrome
Interventions
ZX008 (Fenfluramine Hydrochloride), Matching Placebo
Drug
Lead sponsor
Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
Industry
Eligibility
2 Years to 18 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
San Francisco, California • Aurora, Colorado • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2022 · Synced Sep 30, 2026, 9:08 AM EDT
Not yet recruiting Not applicable Interventional

Overnight TI in TLE

NCT07434986
View directory record Official record
Conditions
Temporal Lobe Epilepsy (TLE), Drug Resistant Epilepsy, Sleep
Interventions
Non-invasive Temporal Interference (TI) Stimulation Targeting Bilateral Hippocampi
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 30, 2026, 9:08 AM EDT
Completed Not applicable Interventional

Ketogenic Diet for Child Epilepsy and Seizure Control

NCT00004729
View directory record Official record
Conditions
Epilepsy, Seizures, Lennox-Gastaut Syndrome
Interventions
Ketogenic diet
Behavioral
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
1 Year to 10 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 22, 2006 · Synced Sep 30, 2026, 9:08 AM EDT
Active, not recruiting Not applicable Interventional

A Pilot Study: Focused Ultrasound Thalamotomy for the Prevention of Secondary Generalization in Focal Onset Epilepsy

NCT03417297
View directory record Official record
Conditions
Partial Seizures With Secondary Generalization, Focal Epilepsy With Secondary Generalization
Interventions
High Intensity Focused Ultrasound
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 15, 2025 · Synced Sep 30, 2026, 9:08 AM EDT
Completed Phase 2 Interventional Results available

Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy

NCT03373383
View directory record Official record
Conditions
Drug-resistant Epilepsy, Focal-Onset Seizures
Interventions
Padsevonil, Placebo
Drug · Other
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
411 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
27
States / cities
Chandler, Arizona • Little Rock, Arkansas • La Jolla, California + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Sep 30, 2026, 9:08 AM EDT
Completed Not applicable Interventional

Investigations of Amygdala Function Using Neurophysiological Recording and Stimulation

NCT03958903
View directory record Official record
Conditions
Fear, PTSD, Panic Disorder
Interventions
Amygdala recording and stimulation using Neuropace RNS, Behavioral tasks
Device · Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 26, 2023 · Synced Sep 30, 2026, 9:08 AM EDT
Terminated Phase 4 Interventional

Effectiveness Study Comparing Treatment With Drug(s) or Adjunctive VNS Therapy for Pharmacoresistant Partial Seizures

NCT00215215
View directory record Official record
Conditions
Epilepsies, Partial
Interventions
Vagus Nerve Stimulation Therapy
Device
Lead sponsor
Cyberonics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
23
States / cities
Phoenix, Arizona • Sun City, Arizona • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2006 · Synced Sep 30, 2026, 9:08 AM EDT
Completed Phase 2 Interventional

Hormone Replacement in Menopausal Women With Epilepsy

NCT00027209
View directory record Official record
Conditions
Menopause, Epilepsy
Interventions
prempro
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
0 Years and older · Female only
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2006 · Synced Sep 30, 2026, 9:08 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Impact of Ketogenic Diets on Cardiovascular Health in Adults With Epilepsy

NCT02694094
View directory record Official record
Conditions
Hypercholesterolemia, Carotid Intimal Medial Thickness 1, Seizure, Epilepsy, Cardiovascular Disease, Cerebrovascular Disease, Heart Disease, Coronary Disease
Interventions
Modified Atkins or Ketogenic Diet
Dietary Supplement
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 30, 2026, 9:08 AM EDT
Completed No phase listed Observational

Registry of Subjects With Drug Resistant Epilepsy and Treated With the VNS Therapy System.

NCT03529045
View directory record Official record
Conditions
Epilepsy, Seizures, Drug Resistant Epilepsy
Interventions
Vagus Nerve Stimulation (VNS) Therapy
Device
Lead sponsor
LivaNova
Industry
Eligibility
Not listed
Enrollment
827 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
19
States / cities
Grand Junction, Colorado • Washington D.C., District of Columbia • Orlando, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2024 · Synced Sep 30, 2026, 9:08 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Modulating Movement Intention Via Cortical Stimulation

NCT03233399
View directory record Official record
Conditions
Seizures, Seizure Disorder, Psychogenic Movement Disorder
Interventions
Sham TMS3 stimulation, rTMS of left or right angular gyrus (AG) or frontal cortex (FC), Anodal tDCS of left or right AG or FC
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Sep 30, 2026, 9:08 AM EDT
Recruiting Not applicable Interventional

Epilepsy Journey-An Executive Functioning Intervention for Teens With Epilepsy

NCT06608966
View directory record Official record
Conditions
Epilepsy in Children, Executive Dysfunction
Interventions
Epilepsy Journey web-based modules, Telehealth with a therapist
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
13 Years to 17 Years
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
3
States / cities
Orange, California • Cincinnati, Ohio • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 30, 2026, 9:08 AM EDT
Recruiting Phase 3 Interventional

A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures

NCT04715646
View directory record Official record
Conditions
Epilepsy
Interventions
Brivaracetam
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
1 Month and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
2
States / cities
Hawthorne, New York • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 30, 2026, 9:08 AM EDT
Completed Phase 4 Interventional Results available

A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset Seizures

NCT03116828
View directory record Official record
Conditions
Epilepsy With Partial On-set Seizures
Interventions
Eslicarbazepine Acetate
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
53
States / cities
Mobile, Alabama • Phoenix, Arizona • Downey, California + 46 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Sep 30, 2026, 9:08 AM EDT
Completed Phase 4 Interventional Results available

Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo

NCT00351611
View directory record Official record
Conditions
Epilepsies, Partial
Interventions
Lyrica (pregabalin), placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2020
U.S. locations
103
States / cities
Mobile, Alabama • Northport, Alabama • Tuscaloosa, Alabama + 57 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Sep 30, 2026, 9:08 AM EDT
Completed Not applicable Interventional

The Effect of Music Periodicity on Interictal Epileptiform Discharges

NCT01515436
View directory record Official record
Conditions
Rolandic Epilepsy, Benign Childhood Epilepsy With Centrotemporal Spikes, Epilepsy, Seizures
Interventions
Mozart alternating with Beethoven, Beethoven alternating with Mozart
Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
5 Years to 12 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 24, 2012 · Synced Sep 30, 2026, 9:08 AM EDT
Completed Phase 1 Interventional

An Open-Label Interaction Study to Look at the Effects of Brivaracetam on Phenytoin When Taken Together in 15 Adult Patients With Epilepsy.

NCT00426673
View directory record Official record
Conditions
Epilepsy
Interventions
Brivaracetam (ucb34714)
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
3
States / cities
Little Rock, Arkansas • Charlottesville, Virginia • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 10, 2008 · Synced Sep 30, 2026, 9:08 AM EDT
Completed Phase 4 Interventional Results available

BEEP Follow Up: Evaluation of Repeatability of Lamotrigine Pharmacokinetics in Epileptic Patients

NCT02404168
View directory record Official record
Conditions
Epilepsy
Interventions
lamotrigine (brand Lamictal), lamotrigine (generic Teva)
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 76 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Sep 30, 2026, 9:08 AM EDT
Not listed Not applicable Interventional

Clinical and Electrographic Changes in Responsive Neurostimulation System (RNS) Patients with Acupuncture Treatment

NCT04677751
View directory record Official record
Conditions
Epilepsy
Interventions
Acupuncture intervention
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
15 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Sep 30, 2026, 9:08 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Cor360: Clinician-Facing Broad-Spectrum Cardiac Phenotyping and Risk Assessment Using COR® Wearable ECG to Inform Outcomes-Oriented Care Pathways

NCT07775976
View directory record Official record
Conditions
Cardiovascular Diseases, Cardiovascular Diseases Risk, Cardiac Conduction System Disease, Bundle/Fascicular Abnormalities, His-Purkinje Disease, Arrhythmias, Cardiac, Rhythm Phenotypes, Myocardial Ischemia, Syncope, Syncope Recurrent, Syncope and Collapse, Seizure Disorder, Sleep Apnea Syndrome, Obstructive, Decision Support Systems, Clinical, Heart Failure - NYHA II - IV, Heart Failure (for Example, Fluid Overload), HRV, Cardiopulmonary, Sudden Cardiac Arrest, Cardiac Arrest (CA), Ventricular Arrhythmias and Cardiac Arrest, Ventricular Fibrillation, QT Dispersion, Atrial Cardiomyopathy
Interventions
COR Wearable ECG Monitoring, Cor360 Clinician-Facing Decision-Aid Reporting
Device · Other
Lead sponsor
Peerbridge Health, Inc
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
2
States / cities
Pasadena, California • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Sep 30, 2026, 9:08 AM EDT